Lucentis (ranibizumab) Letter of Medical Necessity
Lucentis (ranibizumab) PA increasingly requires step therapy through bevacizumab or a ranibizumab biosimilar. LMNs should justify originator selection.
FDA-Approved Indications
- ● neovascular AMD
- ● macular edema following RVO
- ● diabetic macular edema
- ● diabetic retinopathy
- ● myopic CNV
Why Lucentis Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Bevacizumab preferred
- 2. Biosimilar (Cimerli, Byooviz) preferred
- 3. Indication not specified
What to Include in a Lucentis Letter of Medical Necessity
Document indication, baseline acuity, OCT, prior treatments, and rationale for branded ranibizumab over alternatives.
Key clinical evidence to cite:
- ✓ MARINA, ANCHOR, BRAVO, CRUISE, RIDE, RISE
Relevant guidelines:
- 📖 AAO Preferred Practice Patterns
Lucentis Prior Authorization Criteria
Standard criteria across major US payers for Lucentis. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Lucentis
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Lucentis Prior Authorization FAQ
Why was my Lucentis prior authorization denied?
The most common denial reasons for Lucentis are: Bevacizumab preferred; Biosimilar (Cimerli, Byooviz) preferred; Indication not specified.
What should a Lucentis Letter of Medical Necessity include?
Document indication, baseline acuity, OCT, prior treatments, and rationale for branded ranibizumab over alternatives.
Which payers cover Lucentis?
Lucentis is covered by major US payers including Medicare Part B, UnitedHealthcare, Aetna, Cigna, BCBS, though formulary tier and prior authorization criteria vary.